Equasens Société anonyme (EQS) Q1 2026 TU earnings summary

Executive summary

• Q1 2026 revenue reached €61.4 million, up 7.7% reported and 2.9% like-for-like compared to Q1 2025, driven by recurring revenue growth and strong performance in PHARMAGEST, AXIGATE LINK, and MEDICAL SOLUTIONS divisions.

• Successful integration of EREVO and initial revenue from the SÉGUR Wave 2 programme contributed to growth.

• Focus remains on technological innovation, AI integration, and SaaS expansion in healthcare digital solutions.

Financial highlights

• Revenue increased by €4.4 million year-over-year, with €2.5 million from external growth and €0.2 million from SÉGUR Wave 2.

• Maintenance and subscriptions (recurring revenue) rose 8.3% to €27.7 million; software and services up 23.2% to €10.5 million.

• Like-for-like recurring revenue grew €1.2 million (+4.7%), mainly from pharmacy solutions in Italy and electronic invoicing.

Outlook and guidance

• Continued focus on strengthening leadership in digital health solutions in France and Europe.

• Core solutions to be enhanced with AI functionalities and expanded SaaS offerings in the private healthcare cloud.

• Major R&D resources in 2026 dedicated to qualifying software for SÉGUR Wave 2, with phased rollout over two years.